PCRX vs. PRGO, SUPN, NKTR, OMER, ASMB, CPIX, LLY, JNJ, ABBV, and MRK
Should you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), and Merck & Co., Inc. (MRK). These companies are all part of the "pharmaceuticals" industry.
Pacira BioSciences vs. Its Competitors
Pacira BioSciences (NASDAQ:PCRX) and Perrigo (NYSE:PRGO) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, earnings, dividends, analyst recommendations, institutional ownership and valuation.
Perrigo has a net margin of -1.86% compared to Pacira BioSciences' net margin of -18.08%. Pacira BioSciences' return on equity of 13.29% beat Perrigo's return on equity.
Pacira BioSciences has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
In the previous week, Perrigo had 4 more articles in the media than Pacira BioSciences. MarketBeat recorded 12 mentions for Perrigo and 8 mentions for Pacira BioSciences. Pacira BioSciences' average media sentiment score of 1.77 beat Perrigo's score of 1.36 indicating that Pacira BioSciences is being referred to more favorably in the media.
Pacira BioSciences has a beta of 0.48, meaning that its share price is 52% less volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500.
99.7% of Pacira BioSciences shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 6.4% of Pacira BioSciences shares are held by insiders. Comparatively, 0.7% of Perrigo shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Pacira BioSciences currently has a consensus target price of $30.83, indicating a potential upside of 14.84%. Perrigo has a consensus target price of $33.00, indicating a potential upside of 38.80%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Pacira BioSciences.
Summary
Pacira BioSciences beats Perrigo on 11 of the 16 factors compared between the two stocks.
Get Pacira BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacira BioSciences Competitors List
Related Companies and Tools
This page (NASDAQ:PCRX) was last updated on 8/28/2025 by MarketBeat.com Staff
MarketBeat All Access